2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Biological Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5587 Recurrent second-hit DDX41 mutations share a neomorphic function that promotes a plasmacytoid dendritic cell program

Junichiro Kida, MD, PhD, Julianna Fisher, BS2, Emily Stepanchick3, Carmelo Gurnari, MD,PhD4, Yael Kusne, MD, PhD5, Talha Badar, MD6, Terra Lasho, PhD7, Mrinal M. Patnaik, MD, MBBS8, Timothy Chlon, PhD9
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Jacksonville, Florida, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Germline mutations in the RNA-helicase gene DDX41 are the most common cause of inherited predisposition to adult-onset myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). DDX41 germline mutations are heterozygous and predominantly truncating variants, indicative of loss-of-function (LOF). Germline DDX41-mutated carriers that develop MDS/AML will frequently acquire a second-hit DDX41 somatic mutation in the trans allele at disease onset. This mutation is always missense and most commonly causes p.R525H, although other mutations are recurrent, including p.G530D, p.P321L, p.T227M, and p.E345D. Interestingly, the p.P321L variant exhibited significantly higher VAF compared to the other recurrent mutations (Tiong IS, et al. Leukemia. 2026;40). In addition, our analysis revealed that p.P321L showed a marked predominance in MDS rather than AML. Single-cell analysis from biallelic DDX41-mutated MDS/AML patients (2 cases with p.R525H and 1 case with p.T227M) showed that CD34+ leukemic blasts shared immunophenotypic features of plasmacytoid dendritic cell (pDC) (CD123+CD303+). We previously reported that DDX41R525H/- human iPSCs-derived hematopoietic stem and progenitor cells preferentially differentiated into pDCs, indicating that p.R525H has a neomorphic function of skewed differentiation toward pDC (Kida J, et al. the 67th ASH Meeting. 2025). We hypothesized that recurrent somatic mutations (RSMs) in DDX41 share this neomorphic function.

To model the genetics of DDX41-mutated disease, we generated a MOLM13 cell line with a frameshift mutation in one allele of DDX41 to model the germline mutation. Because biallelic DDX41 loss is lethal, we introduced a doxycycline (DOX)-inducible wild-type DDX41 expression cassette before generating second-hit mutations. Then we modified the endogenous allele to cause RSMs (p.R525H, p.G530D, p.P321L, p.T227M) and KO (resulting in double KO) in trans to the existing frameshift mutation. In this manner, we derived MOLM13 cells that would model the recurrent genotypes of DDX41 upon the withdrawal of DOX from the culture.

We observed profound cell growth suppression and cell death upon DOX withdrawal in R525H/-, G530D/-, T227M/- and double-KO. In contrast, only P321L/- showed mild growth suppression and cell death, which was confirmed by increased cleaved caspase-3 by WB. All tested RSMs exhibited pDC-like features shown by upregulated CD123 by flow cytometry and increased IRF7 and SPI-B by WB, whereas double-KO didn’t exhibit these features. Next, we overexpressed RSMs (4 somatic mutations tested in endogenous editing and p.E345D) on double-KO MOLM13 cells. All tested somatic mutations recapitulated the endogenous editing phenotypes, including growth suppression and increased IRF7 and SPI-B: only p.P321L overexpression showed mild cell growth suppression. p.E345D overexpression similarly exhibited profound cell growth suppression and pDC-like features.

Next, to determine whether this function is RSM-specific, we overexpressed (i) two germline missense mutations (p.Y259C and p.Y516C) to test whether germline missense mutations share this function, (ii) p.R525C, an alternative R525 substitution reported in solid tumors but not in MDS/AML, to determine whether the neomorphic activity is specific to the leukemia-associated p.R525H substitution, and (iii) R525H-DDX41 lacking key domain (coiled-coil, DEAD, and C-terminal containing zinc-finger) to examine which domain is required for the activity, on double-KO MOLM13 cells. We observed that (i) neither p.Y259C nor p.Y516C exhibited pDC-like features, (ii) p.R525C didn’t rescue cell growth, and didn’t exhibit pDC-like features, and (iii) none of R525H-DDX41 lacking individual domain exhibited pDC-like features. These results indicate that the specific structural feature of mutant DDX41 caused by RSMs is needed to promote the pDC program.

Among RSMs, p.P321L exhibited mild LOF phenotype. DDX41 structural analysis reported that the RSM sites are located within or adjacent to the ATP-binding region, yet P321 lies outside this region, indicating the helicase activity is less affected. This may contribute to the higher VAF and marked predominant MDS diagnosis observed for p.P321L. Collectively, these findings demonstrate that recurrent second-hit DDX41 mutations converged on a common pDC program despite affecting distinct amino acid residues, providing a potential explanation for the recurrent selection of these mutations during leukemogenesis.

Junichiro Kida, MD, PhD: No relevant conflicts of interest to declare.